Abstract
The highly water-soluble monomethoxypoly(ethyleneglycol) (mPEG) prodrugs of cyclosporin A (CsA) were synthesized. These prodrugs were prepared by initially preparing intermediate in the form of carbonate at the 3′-positions of CsA with chloromethyl chloroformate, in the presence of a base to provide a 3′-carbonated CsA intermediate. Reaction of the CsA intermediate with mPEG derivative in the presence of a base provides the desired water-soluble prodrugs. As a model, we chose molecular weight 5 kDa mPEG in the reaction with CsA to give water soluble prodrugs. To prove that the prodrug is decomposed in the body to produce CsA, the enzymatic hydrolysis test was conducted using human liver homogenate at 37°C. The prodrug was decomposed in human liver homogenate to produce the active material, CsA, and the hydrolysis half-life (t1/2) of the prodrug, KI-306 was 2.2 minutes at 37°C. However, a demonstration of non-enzymatic conversion in pH 7.4 phosphate buffer was provided by the fact that the half-life (t1/2) is 21 hours at 37°C. The hydrolysis test in rat whole blood was also conducted. The hydrolysis was seen with half-life (t1/2) of about 9.9, 65.0, 14.2, 3.4, 2.1 9.5, and 1.6 minutes for KI-306, 309, 312, 313, 315, 316, and 317, respectively. This is the ideal for CsA prodrug. The pharmacokinetic study of the prodrug, KI-306, in comparison to the commercial product (Sandimmune Neoral Solution) was also carried out after single oral dose. Each rat received 7 mg/kg of CsA equivalent dose. Especially, the prodrug KI-306 exhibits higher AUC and Cmax than the conventional Neoral. The AUC and Cmax were increased nearly 1.5 fold. The kinetic value was also seen with Tmax of about 1.43 and 2.44 hours for KI-306 and Neoral, respectively.
Similar content being viewed by others
Referencees
Abella, I., Pharmacoeconomics of Neoral, a new formulation of cyclosporin., in renal transplantation.Transplant Proc., 28, 3131 (1996).
Diasio, R. B. and LoBuglio. A. F., Immunomodulators: immuno-suppressive agents and immunostimulants. In: Hardman, J. G., Goodman, L. S., Gillman, A., Limbird, L. E., eds. Goodman and Gillmans the pharmacological basis of therapeutics [ed. 9].New York, McGraw-Hill, 1291 (1996).
Drewe, J., Beglinger, C., and Kissel, T., The absorption site of cyclosporin in the human gastrointestinal tract.Br. J. Clin. Pharmacol., 33(1), 39–43 (1992).
Fahr, A., Cyclosporin clinical pharmacokinetics.Clin. Pharmacokinet., 24(6), 472–495 (1993). Review.
Faulds, D., Goa, K. L., and Benfield, P., Cyclosporine: a review of its pharmacodynamic and pharmacokinetic propertie., and therapeutic use in immunoregulatory disorders.Drugs, 45, 953 (1993).
Maeda, H., SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy.Adv. Drug Deliv. Rev., 6, 181–202 (1991).
Maeda, H., Seymour, L. W., and Miyamoto, Y., Conjugates of anticancer agents and polymers: advantages of macromolecular therapeuticsin vivo.Bioconjug. Chem., 3, 351–362 (1992).
Matthew, A. E., Mejillano, M. R., Nath, J. P., Himes, R. H., and Stella, V. J., Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity.J. Med. Chem., 35, 145–157 (1992).
McEvoy, G. K., ed. AHFS drug information. Bethesda, M. D.,American Society of Health-System Pharmacists, 3057 (1998).
Noble, S. and Markham, A., Cyclosporine: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).Drugs, 50, 924 (1995).
Noguchi, Y., Wun, J., Duncan, R., Strohalm, R., Ulbrich, K., Akaike, T., and Maeda, H., Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.Jpn. J. Cancer Res., 89, 307–314 (1998).
Shibata, N., Morita, K., Ono, T., Nishikawa, S., Kinoshita, M., Kawakita, S., Takada, K., Muranishi, S., and Shimakawa, H., Effects of diltiazem on Theological properties of human blood.Journal of pharmacobio-dynamics, 11(3), 175–180 (1988).
Strom, T. B. and Tilney, N. L., Immunobiology and immunopharmacology of graft rejection. In: Schrier, R. W., Gottschalk, C. W., eds. Diseases of the Kidney [ed 5]. Boston, Little, Brown, 2879 (1993).
Ymaoka, T., Tabata, Y., and Ikada, Y., Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice.J. Pharm. Sci., 83, 601–606 (1994).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cho, H., Chung, Y. Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. Arch Pharm Res 27, 662–669 (2004). https://doi.org/10.1007/BF02980167
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02980167